About this Research Topic
Gene editing refers to the precise alteration of an organism's DNA sequence at a specific locus. In cancer treatment, this technology is leveraged to modify the genetic makeup of cancer cells, either to disable oncogenes or to restore tumor suppressor gene function. Common gene editing tools include CRISPR-Cas9, TALENs, and ZFNs, with CRISPR-Cas9 being the most widely used due to its simplicity, efficiency, and versatility. Nonetheless, current gene editing methods face significant challenges, such as off-target effects, immunogenicity, and delivery efficiency. Future research, including but not limited to the development of delivery systems, is critically needed to overcome these challenges.
This Research Topic aims to delve into the latest advances and future trends in the field of cancer gene therapy. We seek to highlight the most recent research achievements in this area, focusing on the latest applications of gene editing technologies like CRISPR-Cas9 and their potential benefits in enhancing cancer treatment efficacy and minimizing side effects. We encourage submissions from authors addressing in vivo gene editing therapy using multidisciplinary approaches, including molecular biology, cell biology, genetics, immunology, bioinformatics, biomedical engineering, materials science, and clinical medicine.
Specifically, original research articles or timely reviews that include, but are not limited to, the following topic areas are welcome.
1. The development of novel gene editing tools, methods, and systems in cancer therapy
2. The improvement of delivery vectors and delivery systems for gene editing in cancer therapy
3. Personalized customization of treatment protocols for gene editing in cancer therapy
4. The application of nanomedicine in cancer gene therapy
5. Mechanisms of therapeutic gene editing tools
6. Regulatory issues, ethics and equity of access for patients
This Research Topic aims to delve into the latest advances and future trends in the field of cancer gene therapy. We seek to highlight the most recent research achievements in this area, focusing on the latest applications of gene editing technologies like CRISPR-Cas9 and their potential benefits in enhancing cancer treatment efficacy and minimizing side effects. We encourage submissions from authors addressing in vivo gene editing therapy using multidisciplinary approaches, including molecular biology, cell biology, genetics, immunology, bioinformatics, biomedical engineering, materials science, and clinical medicine.
Specifically, original research articles or timely reviews that include, but are not limited to, the following topic areas are welcome.
1. The development of novel gene editing tools, methods, and systems in cancer therapy
2. The improvement of delivery vectors and delivery systems for gene editing in cancer therapy
3. Personalized customization of treatment protocols for gene editing in cancer therapy
4. The application of nanomedicine in cancer gene therapy
5. Mechanisms of therapeutic gene editing tools
6. Regulatory issues, ethics and equity of access for patients
Keywords: cancer therapy, gene editing, drug delivery, CRISPR/Cas9, nanomedicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
